AstraZeneca may have provided incomplete efficacy data from latest Covid-19 trial — NIAID

BENGALURU (March 23): British drugmaker AstraZeneca Plc may have provided an incomplete view of efficacy data on its COVID-19 vaccine from a large scale U.S. trial, the U.S. National Institute of Allergy and Infectious Diseases (NIAID) said on Tuesday, in a fresh setback to the shot.

AstraZeneca said a day earlier that its COVID-19 vaccine developed with Oxford University was 79% effective in preventing symptomatic illness in a large trial in the United States, Chile and Peru.

To continue reading, please click here

Leave a Reply

Related Articles

Back to top button